Findings from China Medical University Yields New Findings on Lung Cancer (Identification and Validation of a Metabolism-related Model and Associated With Tumor-infiltrating Lymphocytes In P53 Mutant Lung Adenocarcinoma Patients)

摘要

2021 SEP 21 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - A new study on Oncology - Lung Cancer is now available. According to news reporting out of Shenyang, People's Republic of China, by NewsRx editors, research stated, "The immunosuppressive tumor microenvironment produced by cancer cells is a key mechanisms of cancer immune escape. In this study, we investigated the relationship between the metabolic patterns and tumor immune environment in the TME of lung adenocarcinoma (LUAD) with the p53 mutation." Financial support for this research came from National Natural Science Foundation of China (NSFC). Our news journalists obtained a quote from the research from China Medical University, "The clinical data of 495 LUAD patients was obtained from The Cancer Genome Atlas as transcriptomic and somatic mutation data. Using differential analysis, survival analysis, and a LASSO regression model based on metabolic unigenes from KEGG pathways, a tumor metabolic model was constructed to predict the prognosis of LUAD patients. Subsequently, nomogram, receiver operating characteristic, and decision curve analyses were conducted to assess the predictive ability of the model. In addition, the ESTIMATE and CIBERSORT algorithms were used to detect tumor purity and estimate the fractions of 22 immune cell types in each patient, respectively.